Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease treatments, has announced its participation in the upcoming Virtual Life Sciences Investor Forum. Dr. Shalabh Gupta, the company's CEO, will deliver a corporate update on September 19, 2024, at 2:00 p.m. ET.
Investors can access the live and archived webcast through the Unicycive website's Investors section under Events and Presentations. Pre-registration is recommended for online participants to ensure smooth access and receive event updates. The webcast archive will remain available for three months following the presentation.
Unicycive Therapeutics (Nasdaq: UNCY), un'azienda biotech in fase clinica focalizzata sui trattamenti per le malattie renali, ha annunciato la sua partecipazione al prossimo Forum Virtuale per gli Investitori delle Scienze della Vita. Il Dr. Shalabh Gupta, CEO dell'azienda, fornirà un aggiornamento aziendale il 19 settembre 2024, alle 14:00 ET.
Gli investitori possono accedere alla webconferenza dal vivo e all'archivio tramite la sezione Investitori del sito web di Unicycive, sotto Eventi e Presentazioni. Si consiglia la pre-registrazione per i partecipanti online per garantire un accesso fluido e ricevere aggiornamenti sull'evento. L'archivio della webconferenza rimarrà disponibile per tre mesi dopo la presentazione.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biofarmacéutica en etapa clínica centrada en tratamientos para enfermedades renales, ha anunciado su participación en el próximo Foro Virtual de Inversores en Ciencias de la Vida. El Dr. Shalabh Gupta, CEO de la compañía, brindará una actualización corporativa el 19 de septiembre de 2024, a las 2:00 p.m. ET.
Los inversores pueden acceder a la transmisión en vivo y al archivo a través de la sección de Inversores del sitio web de Unicycive en Eventos y Presentaciones. Se recomienda la preinscripción para los participantes en línea para asegurar un acceso fluido y recibir actualizaciones sobre el evento. El archivo de la transmisión permanecerá disponible durante tres meses después de la presentación.
유니사이브 테라퓨틱스 (Nasdaq: UNCY), 신장 질환 치료에 초점을 맞춘 임상 단계의 생명공학 회사가 다가오는 가상 생명 과학 투자자 포럼에 참여한다고 발표했습니다. 샬럽 구프타 박사, 회사의 CEO가 2024년 9월 19일 오후 2시 ET에 기업 업데이트를 제공할 예정입니다.
투자자들은 유니사이브 웹사이트의 투자자 섹션에서 이벤트 및 프레젠테이션 아래에 있는 실시간 스트리밍 및 보관된 웹캐스트에 접근할 수 있습니다. 온라인 참가자는 원활한 접근을 보장하고 행사 업데이트를 받기 위해 사전 등록을 권장합니다. 웹캐스트 아카이브는 프레젠테이션 후 3개월 동안 이용 가능합니다.
Unicycive Therapeutics (Nasdaq: UNCY), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements des maladies rénales, a annoncé sa participation au prochain Forum Virtuel des Investisseurs en Sciences de la Vie. Dr. Shalabh Gupta, le PDG de l'entreprise, présentera une mise à jour de l'entreprise le 19 septembre 2024 à 14h00 ET.
Les investisseurs peuvent accéder au webinaire en direct et à l'archive via la section Investisseurs du site web d'Unicycive sous Événements et Présentations. Il est recommandé de se préinscrire pour les participants en ligne afin d'assurer un accès fluide et de recevoir des mises à jour sur l'événement. L'archive du webinaire sera disponible pendant trois mois après la présentation.
Unicycive Therapeutics (Nasdaq: UNCY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen von Nierenerkrankungen konzentriert, hat seine Teilnahme am kommenden Virtual Life Sciences Investor Forum angekündigt. Dr. Shalabh Gupta, der CEO des Unternehmens, wird am 19. September 2024 um 14:00 Uhr ET ein Unternehmensupdate geben.
Anleger können die Live-Übertragung sowie das Archiv über den Investorenbereich der Unicycive-Website unter Veranstaltungen und Präsentationen abrufen. Für Online-Teilnehmer wird eine Vorregistrierung empfohlen, um einen reibungslosen Zugang zu gewährleisten und Event-Updates zu erhalten. Das Archiv der Webcast bleibt für drei Monate nach der Präsentation verfügbar.
- None.
- None.
LOS ALTOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company" or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Sciences Investor Forum on Thursday, September 19, 2024 at 2:00 p.m. ET in New York, NY.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. An archive of the webcast will be available for three months.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
ir@unicycive.com
(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) presenting at the Virtual Life Sciences Investor Forum?
Who will be presenting the corporate update for Unicycive Therapeutics (UNCY)?
How can investors access Unicycive Therapeutics' (UNCY) presentation at the Virtual Life Sciences Investor Forum?
How long will the webcast of Unicycive Therapeutics' (UNCY) presentation be available?
What is the main focus of Unicycive Therapeutics (UNCY)?
